Search Videos and More
Course
Breast Cancer: New Horizons, Current Controversies
July 20-22, 2023 Live Virtual and In Person Westin Copley Place, Boston, MA
News
Dana-Farber Research Publication, 7.1.2023
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 1 through June 15.
News
Bispecific Antibodies for Multiple Myeloma: Six Things Your Patients Should Know
In 2022, the drug teclistamab became the first bispecific antibody to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.
News
Study Suggests Lymphoma Patients with Depression or Anxiety Experience Shorter Survival Times
Patients with depression and/or anxiety prior to a diagnosis of diffuse large B-cell lymphoma (DLBCL) had shorter survival times than patients without a mental health diagnosis, according to a retrospective study led by Dana-Farber Cancer Institute researchers and published in The Lancet Hematology.
News
Study Uncovers Role of Ultraviolet Radiation in Development of Rare Leukemia in the Skin
A change of scenery can restore one's outlook, but for some precancerous cells, a journey from the caves of the bone marrow to the sunny climes of the skin can trigger genetic changes that are a harbinger of cancer, according to a new study by researchers at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and the Broad Institute of MIT and Harvard.
Symposium
ASCO 2023 Highlights
Dana-Farber physician-scientists shared research and clinical advances at the 2023 Annual Meeting of the American Society of Clinical Oncologists (ASCO).
News
Dana-Farber/Boston Children's Again Ranked Among the Best Pediatric Cancer Programs in the Nation
U.S. News & World Report has named Dana-Farber/Boston Children's Cancer and Blood Disorders Center the #2 pediatric program in the nation in its 2023-24 Best Children's Hospitals report.
Video
ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD
Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer.
Video
ASCO 2023: Treating NUT Carcinoma Research Presented by Jia Luo, MD
Dana-Farber's Jia Luo, MD, details on findings from the NUT Carcinoma Registry on initial chemotherapy for locally advanced and metastatic disease.
Video
ASCO 2023: Breast Cancer Research Presented by Jennifer Ligibel, MD
Women with breast cancer shed pounds thanks to telephone-based weight loss program, clinical trial finds.
Video
ASCO 2023: Kidney Cancer Research Presented by Toni Choueiri, MD
We learn from negative study results as well as from positive ones. Phase 3 study by Dana-Farber's Toni Choueiri, MD, shows that rechallenge with PD-L1 inhibitors in second-line therapy for advanced kidney cancer has no benefit.
Video
ASCO 2023: Breast Cancer Research Presented by Paolo Tarantino, MD
Data from more than 8,000 patients with stage 1A triple-negative breast cancer finds improved 5-year breast-cancer specific survival in those treated with adjuvant chemotherapy whose tumors measured between 1-2 cm.